ICLIO

ICLIO has now become a part of the ACCC Immuno-Oncology Institute. Visit accc-cancer.org/home/learn/imm… to learn more, and please follow @ACCCBuzz for all further updates. #cancer #immunotherapy #immunooncology #IO #oncology

On Demand Webinar: “Testing” the Relationship Between Pathologists, Surgeons and Oncologists accc-iclio.org/resources/dema…

Learn more about the role that the microbiome could play in developing immunotherapies: rebrand.ly/lcq2o

With advances in immunotherapy, it is time for us to reconsider how we approach survivorship: rebrand.ly/4idra

Read about best practices for immuno-oncology agents, including managing inventory, dispensing, and storage: rebrand.ly/qscp1

Watch this replay of our webinar on the role of immuno-oncology biomarkers in lung cancer: rebrand.ly/5aojf #immunotherapy

Our webinar on the role of the microbiome in immunotherapy is now available on-demand! rebrand.ly/41ogi

.@AJMC_Journal summarized the findings of our latest report on immunotherapy, including top priorities for cancer centers and the most significant challenges they face in care delivery: ajmc.com/newsroom/accc-…

We have dozens of webinars archived on a host of topics related to #immunotherapy. Check them all out here: rebrand.ly/3njt

ICLIO Webinar: Managing Immune-Related Adverse Events: Learning from Case Studies rebrand.ly/ikgj

Congratulations to Advocate Medical Group, recipient of our 2017 ICLIO Innovator Award! rebrand.ly/x6gxc

Browse through our most popular immuno-oncology resources: rebrand.ly/h8u70

Creating a Supportive Treatment Environment for I-O Patients rebrand.ly/iwqs

Creating an I-O Program from the Ground Up rebrand.ly/vz5l

The speed of advancement in immunotherapy makes it hard to keep up. Read about new immunotherapies and indications: rebrand.ly/a8i8

ICLIO Webinar: Immuno-Oncology Management Best Practices 2.0 rebrand.ly/h1mv

Managing Adverse Events Associated with I-O Agents e-Course rebrand.ly/a3r9

Managing Patient Expectations Webinar rebrand.ly/t859

Effective management of immune-related adverse events (irAEs) necessitate the incorporation of non-oncology specialists into the I-O team: rebrand.ly/65fhe

A Patient’s Perspective on Immuno-Oncology Treatment for Lung Cancer rebrand.ly/yw4q